WHITEHOUSE STATION, N.J., August 23, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Richard R. DeLuca Jr. as executive vice president and president, Merck Animal Health, effective September 15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck’s president and chief executive officer, and will serve on the company’s Executive Committee. He will succeed Raul Kohan, who has decided to retire from the company. Kohan will remain with the company until the end of the year, reporting to Frazier, to ensure a smooth transition.
As leader of Merck Animal Health, DeLuca will leverage the division's strong product portfolio and customer focus to capitalize on new growth opportunities, including expanding the business in emerging markets. The unit offers veterinarians, farmers, pet owners and governments a broad range of veterinary pharmaceuticals, vaccines and health management solutions and services in more than 50 countries, while its products are available in some 150 markets.
"Merck Animal Health, one of the largest and most profitable animal health businesses in the world, is an integral part of Merck. We believe the business is well positioned in a number of fast-growing segments within the global animal health market," said Frazier. "We are delighted to welcome Rick DeLuca as the new leader of our Animal Health division, with his experience leading and growing international animal health businesses. While Merck Animal Health already has a considerable presence around the world, further global expansion of the business represents a significant long-term growth opportunity for us."
"I also want to thank Raul for his steady leadership in bringing together Intervet and Schering-Plough Animal Health and maintaining the unit's strong performance through the merger and integration of Merck and Schering-Plough to create a highly competitive and valuable animal health franchise," Frazier added. "Raul's contributions to this important part of our business and his development of an experienced senior leadership team, created a firm foundation upon which Rick can build going forward. We appreciate Raul's dedication to ensuring a smooth leadership transition in the coming months before he retires from Merck."
"This is a wonderful time to join Merck, with its commitment to growing its animal health business," said DeLuca. "I look forward to working with the talented managers and employees in ensuring that the division is a best-in-class global animal health leader."
DeLuca served as chief financial officer of BD Biosciences since 2010. Prior to that, he was president of Wyeth's Fort Dodge Animal Health division since 2007. While at Wyeth, DeLuca led a global team across all functions of the business unit with worldwide revenues of over $1 billion.
Prior to leading the Fort Dodge Animal Health division, DeLuca was chief operating officer of Fort Dodge from 2006 to 2007, where he oversaw all sales and marketing activities and implemented growth strategies internationally. He also served as the division's executive vice president and chief financial officer from 2002 to 2006, where he was responsible for all finance and administration, information systems and product supply planning and logistics activities. Prior to that, DeLuca held a variety of managerial roles at Wyeth and elsewhere since 1982.
DeLuca received his bachelor's degree in business administration from Widener University in Chester, Pennsylvania.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2010 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).